Establishment the methods of the measurement of human papillomavirus (HPV) vaccine efficacy and the study for its practical use on cervical cancer eradication

目前在日本商业化的两种人乳头瘤病毒（HPV）疫苗估计能够保护约70%的宫颈癌病例。另一方面，这些HPV疫苗效力的测量方法尚未建立。在本研究中，我们开发了测定血清中16和18抗体的中和型HPV的原始方法，这些类型被认为是宫颈癌最典型的高危因素。我们还实际评估了接种前/接种后的血清，发现HPV疫苗确实提高了抗体水平。

Two kinds of human papillomavirus (HPV) vaccine currently commercialized in Japan are estimated that they would be able to protect approximately 70% of cervical cancer cases. On the other hand, the method of measurement on these HPV vaccine efficacies had not been established yet. In this study, we developed the original methods on measure the neutralized HPV types of 16 and 18 antibodies in sera, types which are known as the most typical high risk factors of cervical cancer, induced by the vaccination. We also practically evaluated pre-/post- vaccinated sera and found that the levels of antibody are certainly increased by HPV vaccine.